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n 1997, United States President Bill 
Clinton announced the challenge 
to develop an AIDS vaccine by 
2007. Since 1997, the AIDS Vaccine 
Advocacy Coalition (AVAC) has 
published annual reports on the global 
status of the effort to meet Clinton’s 
deadline. Last year’s report, entitled 
“AIDS Vaccine Trials—Getting the 
Global House in Order,” ofﬁ  cially 
ends the countdown. Saying that “we 
are on a long term mission,” AVAC 
concludes that there will not be a safe 
and efﬁ  cient vaccine in 2007, and that 
we need to “focus on the long haul 
and set an agenda for sustained and 
sustainable action that stretches well 
beyond 2007.” It is not that there are 
no vaccine candidates in clinical trials, 
but there is little hope that any of the 
current candidates will turn out to be 
a cheap and safe vaccine that affords 
long-term protection. 
Among notable developments 
over the past 12 months, the AVAC 
report highlights the Global HIV/
AIDS Vaccine Enterprise as an effort 
to improve coordination within the 
AIDS vaccine ﬁ  eld. The Enterprise 
was announced in June 2003 and 
now shares its scientiﬁ  c strategic plan 
with everyone affected by the AIDS 
pandemic—that is, all of us—by 
publishing it in PLoS Medicine (DOI: 
10.1371/journal.pmed.0020025). 
In its plan the Enterprise presents 
itself as a global endeavor and 
emphasizes the need for integration 
and capacity building around the 
world. It is not “a discrete organization 
with a pool of money” but a 
“coordinating group of individual 
funding agencies that will support 
speciﬁ  c areas of research using their 
own mechanisms, according to their 
own practices and policies, and 
following the Enterprise’s principles.” 
These principles include collaboration, 
standardization, and coordination 
among international researchers and 
agencies. The plan focuses on speciﬁ  c 
scientiﬁ  c roadblocks that need to be 
overcome, but also looks ahead and 
mentions the need to build capacity 
for product manufacturing and clinical 
trials, and to address regulatory issues.
These are noble goals, and the 
fact that they are stipulated jointly by 
many of the leaders in the ﬁ  eld will 
generate excitement and expectations, 
even though much of what is said has 
been said before. The plan stresses 
collaboration and coordination; there 
are clear beneﬁ  ts from a concerted 
effort. But might a level of competition, 
rather than collaboration, be healthy, 
and, if so, what level of competition 
would work best? The Enterprise 
members seem to have wrestled with 
that question. The plan mentions 
an “appropriate balance between 
productive competition and effective 
collaboration,” and suggests that 
certain incentives could be provided by 
“the funders with greatest ﬂ  exibility.” 
As long as it remains unclear where 
scientiﬁ  c breakthroughs will come 
from, diversity and ﬂ  exibility should be 
encouraged and not stiﬂ  ed. David Ho, 
in his Perspective on the plan (DOI: 
10.1371/journal.pmed.0020036), 
mentions the danger of “group think,” 
and the Enterprise must not fall into 
that trap.
Notably absent from this initial 
plan is any mention of a timeline or 
milestones. The remit of the plan’s 
authors was not to prescribe speciﬁ  c 
research but “to stimulate both 
researchers and funders to explore 
new, more collaborative, cooperative, 
and transparent approaches…in 
addition to continuing the productive, 
high-quality approaches already 
underway.” However, without a 
timeline, the plan fails to convey a 
sense of urgency. This is problematic, 
as any delays in developing a vaccine 
will increase the burden from HIV/
AIDS in the parts of the world that can 
least afford it. To accelerate vaccine 
development, the plan urgently needs 
to be supplemented with a list of 
speciﬁ  c tasks, responsible individuals, 
necessary resources, and allocated time. 
The next document from the 
Enterprise must provide speciﬁ  cs on 
project management, although one 
problem with putting a time frame 
on HIV vaccine development is a 
fundamental one: we do not know 
whether it is actually possible to 
develop a safe and effective vaccine. 
(One assumes the Enterprise members 
agree, though there is no explicit 
acknowledgement of this uncertainty 
in the plan.) Moreover, provided it 
can be done, it is impossible to predict 
when the necessary scientiﬁ  c advances 
will happen. That said, without a list 
of speciﬁ  c projects, project leaders, 
and a time frame for achieving or at 
least evaluating speciﬁ  c goals, it will 
be impossible to deﬁ  ne success and 
failure, review progress, and assure 
internal and external accountability. 
There is another reason why a best-
guess timeline is essential: realistic 
expectations about an AIDS vaccine 
would stress the urgency of combating 
the AIDS pandemic over the next 
decade—and maybe longer—in the 
absence of an effective vaccine. The 
potential beneﬁ  ts of a vaccine cannot 
be overestimated, and its development 
has to be one top priority for the global 
scientiﬁ  c community. But its success 
cannot be taken for granted and will 
come too late for millions. Therefore, 
parallel efforts to prevent or reduce 
transmission and to treat infected 
individuals need to be accelerated now. 
The Enterprise’s plan should be 
hailed as a crucially important outline 
for vaccine development, but the 
goodwill surrounding it won’t last 
unless it is quickly followed up with a 
set of milestones, and a transparent 
process by which progress will be 
measured and course corrections 
implemented.  
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